UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Objective and subjective cognitive impairment following chemotherapy for cancer: A systematic review

Cancer treatment reviews, 2012-11, Vol.38 (7), p.926-934

2012

Volltextzugriff (PDF)

Predicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markers

British journal of cancer, 2017-09, Vol.117 (7), p.913-920

2017

Volltextzugriff (PDF)

Efficacy of first-line atezolizumab combination therapy in patients with non-small cell lung cancer receiving proton pump inhibitors: post hoc analysis of IMpower150

British journal of cancer, 2022-01, Vol.126 (1), p.42-47

2022

Volltextzugriff (PDF)

Phase 1A/1B dose-escalation and -expansion study to evaluate the safety, pharmacokinetics, food effects and antitumor activity of pamiparib in advanced solid tumours

British journal of cancer, 2022-03, Vol.126 (4), p.576-585

2022

Volltextzugriff (PDF)

Olanzapine for chemotherapy-induced nausea and vomiting: a systematic review

Supportive care in cancer, 2014-04, Vol.22 (4), p.1143-1151

2014

Volltextzugriff (PDF)

Correction: Phase 1A/1B dose-escalation and -expansion study to evaluate the safety, pharmacokinetics, food effects and antitumor activity of pamiparib in advanced solid tumours

British journal of cancer, 2022-02, Vol.126 (2), p.310-310

2022

Volltextzugriff (PDF)

A lack of association between BMI and chemoimmunotherapy efficacy in advanced non-small cell lung cancer: Secondary analysis of the IMpower150 and IMpower130 clinical trials

BMC cancer, 2024-03, Vol.24 (1), p.379-8, Article 379

2024

Volltextzugriff (PDF)

Evaluation of sunitinib related drug–drug interactons using a full physiological based pharmacokinetic model

Drug metabolism and pharmacokinetics, 2018-01, Vol.33 (1), p.S65-S65

2018

Volltextzugriff (PDF)

Sorafenib-related generalized eruptive keratoacanthomas (Grzybowski syndrome): a case report

Journal of medical case reports, 2021-09, Vol.15 (1), p.481-481, Article 481

2021

Volltextzugriff (PDF)

Relationship between vemurafenib plasma concentrations and survival outcomes in patients with advanced melanoma

Cancer chemotherapy and pharmacology, 2020-03, Vol.85 (3), p.615-620

2020

Volltextzugriff (PDF)

A 10-year update to the principles for clinical trial data sharing by pharmaceutical companies: perspectives based on a decade of literature and policies

BMC medicine, 2023-10, Vol.21 (1), p.1-400, Article 400

2023

Volltextzugriff (PDF)

Risk factors for MEK-associated retinopathy in patients with advanced melanoma treated with combination BRAF and MEK inhibitor therapy

Therapeutic advances in medical oncology, 2020, Vol.12, p.1758835920944359-1758835920944359

2020

Volltextzugriff (PDF)

The Combination of Metformin and Valproic Acid Induces Synergistic Apoptosis in the Presence of p53 and Androgen Signaling in Prostate Cancer

Molecular cancer therapeutics, 2017-12, Vol.16 (12), p.2689-2700

2017

Volltextzugriff (PDF)

Risk factors for severe rash with use of vemurafenib alone or in combination with cobimetinib for advanced melanoma: pooled analysis of clinical trials

BMC cancer, 2020-02, Vol.20 (1), p.157-157, Article 157

2020

Volltextzugriff (PDF)

Kinase inhibitor pharmacokinetics: comprehensive summary and roadmap for addressing inter-individual variability in exposure

Expert opinion on drug metabolism & toxicology, 2017-01, Vol.13 (1), p.31-49

2017

Volltextzugriff (PDF)

The obesity paradox in early and advanced HER2 positive breast cancer: pooled analysis of clinical trial data

NPJ breast cancer, 2021-03, Vol.7 (1), p.30-30, Article 30

2021

Volltextzugriff (PDF)

Combination Therapies Using Metformin and/or Valproic Acid in Prostate Cancer: Possible Mechanistic Interactions

Current cancer drug targets, 2019-01, Vol.19 (5), p.368-381

2019

Volltextzugriff (PDF)

PSA response to antiandrogen withdrawal: a systematic review and meta-analysis

Prostate cancer and prostatic diseases, 2021-09, Vol.24 (3), p.826-836

2021

Volltextzugriff (PDF)

Clinical and functional outcomes for risk‐appropriate treatments for prostate cancer

BJUI compass, 2024-01, Vol.5 (1), p.109-120

2024

Volltextzugriff (PDF)

C-reactive protein provides superior prognostic accuracy than the IMDC risk model in renal cell carcinoma treated with Atezolizumab/Bevacizumab

Frontiers in oncology, 2022-08, Vol.12, p.918993-918993

2022

Volltextzugriff (PDF)

Examining the Priorities, Needs and Preferences of Men with Metastatic Prostate Cancer in Designing a Personalised eHealth Exercise Intervention

International journal of behavioral medicine, 2021-08, Vol.28 (4), p.431-443

2021

Volltextzugriff (PDF)

Protocol for the Flinders Kidney Health Registry: patient outcomes of kidney cancers and nephrectomies

BMC urology, 2022-07, Vol.22 (1), p.1-112, Article 112

2022

Volltextzugriff (PDF)

Early tumor shrinkage identifies long-term disease control and survival in patients with lung cancer treated with atezolizumab

Journal for immunotherapy of cancer, 2020-06, Vol.8 (1), p.e000500

2020

Volltextzugriff (PDF)

Gynecologic Cancer InterGroup (GCIG) Consensus Review for Carcinoid Tumors of the Ovary

International journal of gynecological cancer, 2014-11, Vol.24 (9 Suppl 3), p.S35-S41

2014

Volltextzugriff (PDF)

381 SUPLEXA, a multimodal autologous cellular therapy, shows immunomodulatory behavior in cancer patients consistent with improved anti-tumor immune function

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A430-A430

2023

Volltextzugriff (PDF)

1 – 25 von 182

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(170)
Mit Volltextzugriff
(153)

Publikationsform

Artikel
(181)
Berichte
(1)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Objective and subjective cognitive impairment following chemotherapy for cancer: A systematic review

Predicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markers

Efficacy of first-line atezolizumab combination therapy in patients with non-small cell lung cancer receiving proton pump inhibitors: post hoc analysis of IMpower150

Phase 1A/1B dose-escalation and -expansion study to evaluate the safety, pharmacokinetics, food effects and antitumor activity of pamiparib in advanced solid tumours

Olanzapine for chemotherapy-induced nausea and vomiting: a systematic review

Correction: Phase 1A/1B dose-escalation and -expansion study to evaluate the safety, pharmacokinetics, food effects and antitumor activity of pamiparib in advanced solid tumours

A lack of association between BMI and chemoimmunotherapy efficacy in advanced non-small cell lung cancer: Secondary analysis of the IMpower150 and IMpower130 clinical trials

Evaluation of sunitinib related drug–drug interactons using a full physiological based pharmacokinetic model

Sorafenib-related generalized eruptive keratoacanthomas (Grzybowski syndrome): a case report

Relationship between vemurafenib plasma concentrations and survival outcomes in patients with advanced melanoma

A 10-year update to the principles for clinical trial data sharing by pharmaceutical companies: perspectives based on a decade of literature and policies

Risk factors for MEK-associated retinopathy in patients with advanced melanoma treated with combination BRAF and MEK inhibitor therapy

The Combination of Metformin and Valproic Acid Induces Synergistic Apoptosis in the Presence of p53 and Androgen Signaling in Prostate Cancer

Risk factors for severe rash with use of vemurafenib alone or in combination with cobimetinib for advanced melanoma: pooled analysis of clinical trials

Kinase inhibitor pharmacokinetics: comprehensive summary and roadmap for addressing inter-individual variability in exposure

The obesity paradox in early and advanced HER2 positive breast cancer: pooled analysis of clinical trial data

Combination Therapies Using Metformin and/or Valproic Acid in Prostate Cancer: Possible Mechanistic Interactions

PSA response to antiandrogen withdrawal: a systematic review and meta-analysis

Clinical and functional outcomes for risk‐appropriate treatments for prostate cancer

C-reactive protein provides superior prognostic accuracy than the IMDC risk model in renal cell carcinoma treated with Atezolizumab/Bevacizumab

Examining the Priorities, Needs and Preferences of Men with Metastatic Prostate Cancer in Designing a Personalised eHealth Exercise Intervention

Protocol for the Flinders Kidney Health Registry: patient outcomes of kidney cancers and nephrectomies

Early tumor shrinkage identifies long-term disease control and survival in patients with lung cancer treated with atezolizumab

Gynecologic Cancer InterGroup (GCIG) Consensus Review for Carcinoid Tumors of the Ovary

381 SUPLEXA, a multimodal autologous cellular therapy, shows immunomodulatory behavior in cancer patients consistent with improved anti-tumor immune function

Suchergebnisse filtern